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RESEARCH ARTICLE Open Access
Methylenetetrahydrofolate Reductase Gene
Variant (MTHFR C677T) and Migraine: A Case
Control Study and Meta-analysis
Zainab Samaan1*, Daria Gaysina2, Sarah Cohen-Woods2, Nick Craddock3, Lisa Jones4, Ania Korszun5, Mike Owen3,
Andrew Mente6, Peter McGuffin2 and Anne Farmer2
Abstract
Background: Migraine is a common disorder that often coexists with depression. While a functional polymorphism
in methyleneterahydrofolate reductase gene (MTHFR C677T) has been implicated in depression; the evidence to
support an association of MTHFR with migraine has been inconclusive. We aim to investigate the effect of this
variant on propensity for migraine and to perform a systematic review and meta-analysis of studies of MTHFR and
migraine to date.
Methods: Individuals with migraine (n = 447) were selected from the Depression Case Control (DeCC) study to
investigate the association between migraine and MTHFR C677T single nucleotide polymorphism (SNP) rs1801133
using an additive model compared to non-migraineurs adjusting for depression status. A meta-analysis was
performed and included 15 studies of MTHFR and migraine.
Results: MTHFR C677T polymorphism was associated with migraine with aura (MA) (OR 1.31, 95% CI 1.01-1.70,
p = 0.039) that remained significant after adjusting for age, sex and depression status. A meta-analysis of 15 case-
control studies showed that T allele homozygosity is significantly associated with MA (OR = 1.42; 95% CI, 1.10-1.82)
and total migraine (OR = 1.37; 95% CI, 1.07-1.76), but not migraine without aura (OR = 1.16; 95% CI, 0.36-3.76). In
studies of non-Caucasian population, the TT genotype was associated with total migraine (OR= 3.46; 95% CI, 1.22-
9.82), whereas in studies of Caucasians this variant was associated with MA only (OR = 1.28; 95% CI, 1.002-1.63).
Conclusions: MTHFR C677T is associated with MA in individuals selected for depression study. A meta-analysis of
15 studies supports this association and demonstrated effects across ethnic groups.
Background
Migraine is a common primary headache disorder char-
acterised by recurrent headaches associated with gastro-
intestinal, neurological and autonomic symptoms [1].
Migraine is sub classified further into several types, the
most commonly noted are migraine with aura (MA)
where aura symptoms, usually visual, precede the head-
ache, and migraine without aura (MO). These common
types of migraine are often reported to co occur with
depression [2-5] making the screening for migraine in
individuals with depression and vice versa an important
clinical assessment with impact on diagnosis, treatment
and prognosis. The screening for migraine in depression
also has a significant impact for research where the find-
ings may be confounded by the presence of another disor-
der. It is known that both conditions have a genetic
background [6-8]. A common polymorphism from the
MTHFR gene, the C677T, has been reported to be asso-
ciated with both migraine and depression independently.
The MTHFR gene is located on chromosome 1p36.3 and
encodes for a key enzyme for the metabolism of folate and
homocysteine [9]. The MTHFR 677C to T transmission is
characterized by a point mutation resulting in a valine
substitution for an alanine in this enzyme. Individuals with
the homozygous (TT) state for this mutation showed
higher levels of plasma homocysteine [9]. Homocysteine
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acts as an excitatory amino acid and may influence the
threshold for migraine headache. High homocysteine
levels are seen in individuals with migraine with aura [10].
A number of studies have found a significant associa-
tion between the TT genotype and migraine [11-14];
especially MA [15] inconsistently [16,17].
The MTHFR C677T polymorphism has been reported
to be associated with depression [18]; while other stu-
dies failed to show this association [19].
To our knowledge previous studies have investigated
this gene variant in either cases of depression alone, or
migraine alone without controlling for the presence of
the other condition. We hypothesize that the MTHFR
C677T polymorphism is a migraine gene and the asso-
ciation with depression is due to the presence of
migraine in the individuals studied. In this study, we
investigate the association between MTHFR C677T
polymorphism and migraine in a sample of cases of
depression and healthy controls. A meta-analysis of stu-
dies of this variant and migraine is also reported.
Methods
1. Case Control Study
The study subjects were recruited for a genetic case-
control association study of recurrent major depression,
the Depression Case Control study (DeCC). The sample
selection and recruitment have been described in detail
[20]. Briefly, depression cases (18 years or older) of Cau-
casian origin with a recurrent depressive disorder were
recruited from 3 sites in the UK (London, Cardiff and
Birmingham). Control subjects were selected from the
UK general practice based GENESiS study [21] and
were included in the study if they were of Caucasian ori-
gin with no past or current psychiatric disorder. All sub-
jects gave written informed consent. Local ethics
committees of the study centres approved the study.
Depression Diagnosis
All depression cases were given a face to face diagnostic
interview, the Schedule for Clinical Assessment in Neu-
ropsychiatry (SCAN) [22], administered by trained inter-
viewers to establish the diagnosis of recurrent
depression. Control subjects were interviewed by tele-
phone using the Past History Schedule [23] and were
included if there was no evidence of past or present psy-
chiatric disorder.
Migraine Diagnosis
For the lifetime diagnosis of migraine the structured
migraine interview (SMI) [24] based on the ICHD [1]
was used. Detailed questions about the presence of
headache, severity, frequency, duration, site, type, aura
symptoms and associated symptoms (nausea, vomiting,
sensitivity to light and sound) were obtained. Depression
cases were interviewed face to face and the control sub-
jects were interviewed by telephone. Subjects were
assigned a diagnosis of MA, MO, probable migraine
(PM), no recurrent headaches and non-migraine
headaches.
DNA Samples
DNA samples were obtained from whole blood or buc-
cal epithelial cells for molecular genetic analysis. Whole
blood samples were collected at the time of the inter-
view for all cases with depression that consented for the
genetic portion of the study. Interviewers collected
25 ml of blood from peripheral veins in the anticubital
fossa. Blood samples were collected in Monovettes tubes
containing EDTA. Each tube was rolled gently after
blood collection was completed and stored at room
temperature until the end of the interview where it was
then transferred to the local lab for storage at -20°C
freezer in upright position. In addition, blood drops
from Monovettes tubes were placed on Buffy Coat. All
samples (tubes and Buffy Coat) were labelled with a
unique ID number and bar codes were placed on the
tubes and Buffy Coat. Control subjects were sent cheek
swabs (labelled with unique barcode ID) and instruc-
tions on how to obtain buccal swab samples and were
supplied with return addressed envelopes. DNA was
extracted in house from both whole blood and buccal
mucosa samples following validated procedures as
described earlier [19]. Genotyping of the MTHFR
C677T SNP rs1801133 was performed by KBioscience
(Hoddesdon, Hertz, UK, http://www.kbioscience.co.uk),
blinded to the phenotype status. Full details of the geno-
typing methods and primers design were previously
described [19].
Statistical Analysis
Data were entered into SPSS version 14 for Windows
and statistical analyses were performed using chi square
statistic and logistic regression analysis. Genotype and
allele frequencies were investigated for association with
migraine using contingency tables and chi square statis-
tic. To test for specific association between MA and
MTHFR C677T, logistic regression was used with MA
as dependent variable and age, sex and depression were
entered as co variables.
2. Meta-analysis
Two investigators (ZS and AM) searched databases
(Pubmed, Google Scholar and Embase) for studies of
MTHFR and migraine up to July 2010 (published in
English). Search terms included “MTHFR”, “methylene-
tetrahydrofolate reductase”, “gene”, “genetic variant”,
“polymorphism”, “rs1801133”, “headache”, “migraine”,
“migraine with aura” and “migraine without aura”. Stu-
dies were included if they employed a case-control
design, migraine as the primary outcome and data were
available to extract or calculate OR and 95% CI. Data
from primary studies were extracted by ZS and AM
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independently and entered into excel database. Any dis-
crepancy between investigators’ findings was clarified
and agreement reached by consensus. Fifteen studies
including the current case control study were included
in the analysis. These studies are presented in Table 1.
For the statistical analysis, we used commercially avail-
able statistical software (Comprehensive Meta Analysis
software, version 2.2 [Biostat, Englewood, New Jersey]).
Statistical heterogeneity across studies was assessed
using the Q statistic, with significant heterogeneity for all
of the migraine outcomes. Summary estimates were cal-
culated using a general variance-based method (random-
effects model) with 95% CI [25]. Stratified analyses were
also conducted by ethnic ancestry (European or non-Eur-
opean). Since one study included women participants
only, a sensitivity analysis was conducted whereby this
one study was excluded from the analysis to determine
whether the parameter estimates are altered.
Results
The sample characteristics are presented in Table 2.
Both the migraine and non-migraine groups were in
their 5th decade of life with mean age of 47 years.
Women were more likely to have migraine and indivi-
duals with migraine were more likely to be depressed.
Genotype and allele frequencies for the MTHFR gene
C677T SNP were analysed for 810 (95% genotyping reac-
tion success) psychiatrically healthy controls and 1039
(83% genotyping success rate) depression cases. The con-
trols’ genotype frequencies were in Hardy-Weinberg
Equilibrium (HWE) (c2 = 0.01, df = 1, p = 0.92).
MTHFR C677T polymorphism and migraine
Allele and genotype frequencies for the MTHFR C677T
variant were investigated in migraine. Migraine cate-
gories were assigned as follows:
• No migraine headache including no recurrent
headache and non-migraine headaches.
• Migraine including MA, MO and PM.
• MA only.
Table 3 shows the allele and genotype frequencies for
the different migraine categories. T allele and TT geno-
type were more frequent in MA. Significant statistical
difference was seen in T allele frequencies between MA
and no migraine groups (c2 = 5.45, df = 1, p = 0.02, OR
= 1.37, 95% CI 1.04 - 1.80). No statistical difference was
detected between migraine (including MA, MO and
PM) and no migraine in the T allele frequency (36.7%
vs 34.2%, c2 = 1.9, df = 1, p = 0.17, OR = 1.12, 95% CI
0.95 - 1.31). However, TT genotype was significantly dif-
ferent between MA and no migraine groups (c2 = 4.87,
df = 1, p = 0.027, OR = 1.8, 95% CI 1.03 - 3.16).
The effect of sex was explored in the analysis and
showed excess T allele frequency in women with MA
(c2 = 8.22, df = 1, p = 0.004, OR = 1.53, 95% CI 1.13 -
2.07) and TT genotype (c2 = 7.47, df = 1, p = 0.006, OR
= 2.20, 95% CI 1.19 - 4.07).
In order to investigate the association between MA
and MTHFR C677T adjusting for sex and depression
status we performed logistic regression analysis using an
additive model with MA as the dependant variable and
Table 1 Migraine and MTHFR case control studies
Migraine Population Cases Controls OR (95%CI) Reference
MA British Caucasian 124 1725 1.3 (1.01-1.70) Current
MA North Indian 67 150 1.295“a” (0.676-2.478) [44]
MA Portuguese 78 397 0.48 (0.18-1.23) [29]
MA Italian 100 105 2.48 (1.11-5.58) [39]
MA, MO Italian 105 (90 MO and 15 MA) 97 MA: 2.16 (0.64-7.41) MO: 2.04 (0.98-4.22) [45]
MA Italian 33 (5-17 yr old) 66 (Adults) 2.18 (0.68, 7) [46]
MA “b” USA Caucasian female only 1275 23726 0.79 (0.65-0.96) [26]
MA Japanese 22 261 6.5 (2.5-16.8) [12]
MA, MO Turkish 93(23 MA; 70 MO) 136 MA: 3.05 (0.39-24.51) MO: 7.44 (1.70-32.34) [11]
MA, MO Spanish Caucasian 230 (78 MA and 152 MO) 204 MA: 1.37 (0.63-2.94) MO: 0.59 (0.27-1.24) [15]
MA Australian Caucasian 168 269 2.54 (1.37-4.71) [13]
MA, MO Spanish Caucasian 329 (138 MA and 191 MO) 237 MA: 2.4 (0.8-7.2) MO: 0.28 (0.1-0.8) [37]
MA Dutch 187 1212 2.05 (1.2-3.4) [14]
MA German 656 625 0.87 (0.61-1.25) [16]
MA Finnish 898 900 0.98 (0.84-1.15) “c” [17]
MA migraine with aura, MO migraine without aura. OR for T/T genotype of MTHFR C677T polymorphism. “a” CT genotype is the reference point. MA n = 67, 0%
TT genotype, 69.9% CC, 30.1% CT. healthy controls n= 150, TT 2%, CC 72% and CT 26%.
“b” self reported migraine with aura. “c” OR for T allele frequency in cases and controls. 12.7% of cases did not fulfil criteria for MA based on the International
Headache Society Criteria for MA. MA here is therefore used as a broad definition.
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age, sex and depression as the explanatory variables.
Excess T allele was significantly associated with MA
(OR 1.31, 95% CI 1.01-1.70, p = 0.039). Summary of the
logistic regression results is shown in Table 4.
Meta-analysis
All studies (15 [100%]) (Table 1) assessed MA, while
some (4 [26.7%]) also evaluated MO, and 1 (6.7%) exam-
ined tension headache. In total, the 15 studies included
N = 4,374 migraine cases and N = 30,110 controls.
Table 1 summarizes the characteristics and results of
the included case-control studies by migraine type.
Among the 15 studies included in the meta-analysis, 12
studies enrolled participants of European ancestry, while
3 studies recruited participants of non-European ances-
try. Almost all of the studies (14 [93.3%]) included both
men and women.
The pooled analyses of case-control studies employing
an additive model showed that T allele homozygosity
was significantly associated with MA (OR = 1.42; 95%
CI, 1.10-1.82) and total migraine (OR = 1.37; 95% CI,
1.07-1.76), but not with MO (OR = 1.16; 95% CI, 0.36-
3.76) (Table 5). In a sensitivity analysis that excluded 1
study, which enrolled only women, the parameter esti-
mates remained virtually the same (Table 5). Forest
plots summarizing the effect of this variant on migraine
in each of these studies are shown in Figure 1 for
migraine with aura and Figure 2 for migraine without
aura. Significant heterogeneity across studies was found
both overall (p < 0.0001) and by migraine type (p <
0.0001 for each type).
Table 5 shows the summary estimates for each
migraine type by ethnic origin. In studies of European
ancestry, there was a significant association between TT
genotype and MA (OR = 1.28; 95% CI, 1.002-1.63), but
not with MO (OR = 0.73; 95% CI, 0.24-2.24) or total
migraine (OR= 1.20; 95% CI, 0.95-1.53). Conversely, in
studies of non-European origin, the TT genotype was
not significantly associated with MA (OR = 2.81; 95%
CI, 0.84-9.44) but was associated with total migraine
(OR= 3.46; 95% CI, 1.22-9.82), and there was only 1
study that evaluated MO.
An assessment of the funnel plot of case-control
studies of the C667T polymorphism and migraine sug-
gested a slight publication bias (Figure 3). Point esti-
mates from smaller studies, with greater variability, were
more likely to be distributed on the positive side of the
mean effect size. Egger’s regression test showed border-
line evidence of publication bias (Egger test of the inter-
cept, P = 0.03).
Discussion
We report a significant association between a common
SNP (rs1801133) in the MTHFR gene and MA in a
well-characterized sample of depressed cases compared
to psychiatrically healthy controls. Previous reports have
shown an association between this SNP and depression.
In fact, the association between MTHFR polymorphism
and MA remained significant after adjusting for depres-
sion suggesting that this association is unique to MA.
Table 2 Sample Characteristics
Categorical Variables No Migraine N = 1402 Any Migraine N = 447 c2 p
Female N [%] 951 [59.7] 284 [76.3] 60.3 < 0.0001
Depression N [%] 851 [53.5] 286 [76.9] 105.4 < 0.0001
Married/cohabiting N [%] 422 [26.5] 121 [32.5] 2.3 0.13
≥ 1 Child N [%] 479 [30.1] 65 [17.5] 4.4 0.04
Currently employed N [%] 263 [16.5] 55 [14.8] 1.9 0.16
≥ 12 years education N [%] 207 [13.0] 77 [20.7] 0.36 0.55
Continuous Variables t p
Age in year [SD] 47.7 [± 11.14] 46.9 [± 11.7] 1.4 0.16
SD Standard Deviation.
Table 3 rs1801133 genotype and allele frequency
Genotype No Migraine
N [%]
Any Migraine
N [%]
Migraine with Aura
N [%]
TT 181 [12.9] 62 [14.0] 23 [18.5]
CT 596 [42.5] 204 [46.0] 57 [46.0]
CC 625 [44.6] 181 [40.0] 44 [35.5]
Alleles
T 958 [34.2] 328 [36.7] 103 [41.5]
C 1846 [65.8] 566 [63.3] 145 [58.5]
Table 4 Summary results of logistic regression analysis
Variable OR 95% CI p
Age (year) 1.0 0.98-1.02 0.96
Sex 2.7 1.64-4.40 < 0.0001
Depression 3.7 2.29-6.13 < 0.0001
rs1801133 1.3 1.01-1.70 0.039
Presence or absence of migraine with aura is the dependent variable
OR Odds Ratio.
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No statistically significant association was seen between
this SNP and depression or MO in this study. The asso-
ciation between MTHFR C677T polymorphism and MA
was stronger in women, however remained significantly
associated with MA after controlling for sex, age and
depression. Several studies suggested an association
between MTHFR C677T polymorphism and migraine as
described earlier. Similarly, our meta-analysis of 15 case-
control studies showed that the T allele is significantly
associated with MA and total migraine, the association
with total migraine is most likely accounted for by the
presence of migraine with aura. Conversely other studies
found the TT genotype protective for MA [26-29]. A
meta analysis [30] pooled data from 2961 cases of
migraine reported a significant association between TT
genotype and MA only (OR 1.30, 95% CI 1.06-1.58).
More recently, a meta-analysis of studies published up
to March 2009, reported a significant association
between migraine with aura and MTHFR C677T poly-
morphism (OR 1.48, 95% CI 1.02-2.13) that was mainly
driven by non-Caucasian populations [31]. Our meta-
analysis included 2 additional studies and found that
this genetic variant is associated with total migraine in
non-Caucasian populations and with migraine with aura
in Caucasians. Furthermore, it has been suggested that
this polymorphism was also associated with depression
[18,32-35], we have reported previously that there was
no significant association between depression and this
SNP [19] and we argue that the previous reports of
MTHFR C677T association with depression can be
explained by the high prevalence of migraine in
depressed subjects included in these studies. None of
the studies reported have screened subjects for migraine.
Since migraine can be present in almost a third of parti-
cipants [2], it is likely that the association between
MTHFR C677T and depression is actually an association
with migraine.
In this depression case control study, we found
migraine to be significantly associated with excess T
allele and TT genotype of the MTHFR C677T poly-
morphism. This association was specific only to MA.
Broad migraine (including MA, MO and PM) was not
Table 5 Meta-analysis summary odds ratios (95% CI) for the association of the T allele homozygosity with migraine
All migraine MA only MO only
(15 studies) (15 studies) (4 studies)
N = 4,365 cases N = 3,862 cases N = 503 cases
N = 30,110 controls N = 30,110 controls N = 674 controls
All studies 1.37 (1.07-1.76) “a” 1.42 (1.10-1.82) “a” 1.16 (0.36-3.76)
Excluding 1 study of women only “b” 1.46 (1.11-1.92) “a” 1.54 (1.17-2.02) “a” 1.16 (0.36-3.76)
Ethnic ancestry
European 1.20 (0.95-1.53) 1.28 (1.002-1.63) “a” 0.73 (0.24-2.24)
Non-European 3.46 (1.22-9.82) “a” 2.81 (0.84-9.44) ————— “c”
“a” Statistically significant.
“b” All studies included men and women except for Schurks et al 2008 which enrolled only women.
“c” No summary OR was computed, since there was only 1 study.
Study name Outcome Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value
Current study MA 1.300 1.010 1.673 0.042
Joshi et al., 2009 MA 1.295 0.676 2.481 0.436
Ferro et al., 2008 MA 0.480 0.180 1.280 0.142
Pezzini et al., 2007 MA 2.480 1.110 5.541 0.027
de Tommaso et al., 2007 (MA) MA 2.160 0.640 7.290 0.215
Bottini et al., 2006 MA 2.180 0.680 6.989 0.190
Schürks et al., 2008 MA 0.790 0.650 0.960 0.018
Kowa et al., 2000 MA 6.500 2.500 16.900 0.000
Kara et al., 2003 (MA) MA 3.050 0.390 23.853 0.288
Oterino et al., 2004 (MA) MA 1.370 0.630 2.979 0.427
Lea et al., 2004 MA 2.540 1.370 4.709 0.003
Oterino et al., 2005 (MA) MA 2.400 0.800 7.200 0.118
Scher et al., 2006 MA 2.050 1.200 3.502 0.009
Todt et al., 2006 MA 0.870 0.610 1.241 0.442
Kaunisto et al., 2006 MA 0.980 0.840 1.143 0.797
0.1 0.2 0.5 1 2 5 10
Favours A Favours B
Meta Analysis
Overall 1.42 1.10 1.82 0.007
Odds ratio (95% confidence interval)
0.01 1 2 40.50.2 8
Figure 1 Meta-analysis results of studies examining the effect of the C667T polymorphism on MA headache.
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significantly different than non-migraine headaches in
their T allele and TT genotype distribution. This trend
was also shown in previous studies in different popula-
tions as described earlier. The results were not always
consistent however and other studies reported negative
findings. A relatively large study failed to show an asso-
ciation between migraine and MTHFR C677T poly-
morphism [17]. Such contradictions can be explained in
part by methods of identification of migraine, the differ-
ent populations (clinical, epidemiological samples), age
and sex of the study participants, ethnic variations and
geographic sites included in these studies. Studies have
shown that there are genetic variations across different
populations and geographic locations; these variations
may have a significant role in genetic studies findings
when different populations were included. A small Japa-
nese study (n = 22) was the first to report a significant
association between MTHFR C677T and MA [12] repli-
cated by several other small studies (Korean n = 34 [36],
Spanish n = 60 [37] and Italian n = 33 [38]) while large
German (n = 656) and Finish (n = 898) studies failed to
show significant association between MA and this poly-
morphism [16,17]. These observations were in parallel
with our meta-analysis by subgroups, which showed a
strong and significant association between TT genotype
and migraine in non-Europeans, although we also
observed a modest but significant association with MA
among Caucasians. This ethnic specific association
between a genetic variant and phenotype highlights the
importance of ethnic variations in genetic studies and
the need to expand studies beyond one ethnic group. In
addition, ethnic variation may be a reflection of health
behaviour and life style factors such as dietary habits
and policies on folic acid fortification of diet and supple-
ments. In addition to the different population studied,
there is also a significant variation in migraine case
identification that added further heterogeneity to the
reported studies. The diagnosis of migraine, like depres-
sion, is mainly based on careful history taking of specific
symptoms that show repeated patterns over time and
lack of significant findings in physical examination.
Objective measures to confirm or deny the diagnosis of
migraine are not yet available and therefore the methods
of identification of migraine cases are important sources
of heterogeneity and conflicting results in the literature
of migraine genetics. Our findings of significant
Study name Outcome Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value
de Tommaso et al., 2007 (MO) MO 2.040 0.980 4.247 0.057
Kara et al., 2003 (MO) MO 7.440 1.700 32.561 0.008
Oterino et al., 2004 (MO) MO 0.590 0.270 1.289 0.186
Oterino et al., 2005 (MO) MO 0.280 0.100 0.784 0.015
0.1 0.2 0.5 1 2 5 10
Favours A Favours B
Meta Analysis
Overall 1.16 0.36 3.76 0.80
Odds ratio (95% confidence interval)
0.01 1 2 40.50.2 8
Figure 2 Meta-analysis results of studies examining the effect of the C667T polymorphism on MO headache.
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association between MA and MTHFR C677T in a well
characterised study of 1849 subjects (migraine cases =
447) replicates earlier studies of moderate size
[13,14,39] suggesting a role for the MTHFR gene in
migraine especially MA. Further meta analysis of 13
studies reported a pooled OR = 1.48, 95% CI 1.02-2.13,
for MA only [31]. This may also indicate that the
MTHFR gene effect is associated with aura symptoms
specifically rather than migraine in general. It will be
interesting to investigate homocysteine (a risk factor for
stroke [40]) and folate levels, low folate levels have been
reported in depression [41], in subjects with migraine
with aura to confirm the association between MTHFR
mutation and its function by measuring the end pro-
ducts of the enzyme. A small open label trial of folic
acid administration in children with migraine, hyperho-
mocysteinaemia and MTHFR C677T polymorphism
(TT genotype) reported a reduction in migraine symp-
toms in this population [42]. In a study of 136 indivi-
duals with migraine with aura compared to controls,
homocysteine level was higher in the migraine group
[10]. The homocysteine level was also higher in MA
compared to MO [43]. Randomized controlled trials are
needed to confirm such findings, the results of which
will be valuable for clinical practice in the management
of migraine and depression.
Our results showed that excess T allele and homozy-
gous TT genotype of the MTHFR gene C677T poly-
morphism is associated with increased risk for MA
regardless of depression status. Our case control study
showed that individuals carrying this genetic variant are
30% more likely to have migraine with aura and meta-
analysis strengthened this observation and reported 42%
increase in risk for such individuals, however it is
important to keep in context that this 42% risk increase
for MA is only in individuals carrying this genetic var-
iant, the number of which is relatively small compared
to the general population. The importance of our find-
ings can be focused into 2 main areas:
1st studies of the MTHFR C677T variant are common
especially in psychiatric and cardiovascular fields. These
studies, we encourage, must take into consideration the
common co occurrence of migraine in these disorders
and the strong and reproducible association between
this variant and migraine with aura. It is advisable there-
fore to screen and adjust for migraine in these studies to
avoid spurious associations.
2nd individuals carrying this variant (although a small
number of individuals are carrying the TT genotype var-
iant) are at 42% increased risk for migraine with aura. In
the light of increasing interests in personalised medicine,
adding folate supplements to individuals at risk (a speci-
fically targeted intervention for population at risk) may
mitigate future development of migraine with aura.
The main strengths of our study are the use of vali-
dated diagnostic tool to identify migraine and the use of
direct interviewing of all participants. Our study partici-
pants are also relatively homogenous (of Caucasian eth-
nicity, residing in the UK) thus reducing population
stratification that can have a confounding effect. There
are however certain weaknesses to our study. The study
recruitment was designed to select depressed cases,
which may have led to ascertainment bias. However
migraine was systematically screened for in all partici-
pants and we have adjusted for depression status in our
analysis. In addition our sample size did not allow for
subgroup analysis of each headache type and therefore
we are not able to report whether there is any associa-
tion between this SNP and other types of primary head-
ache disorders in addition to MA such as tension type
headache.
Conclusions
The current study adds to the growing evidence for the
role MTHFR C677T gene variant in migraine with aura.
Our meta-analysis showed a significant association
between this genetic variant and MA in Caucasian
population and overall migraine in non-Caucasian popu-
lation, although the effect in this case is very likely to be
due to MA than migraine in general. Heterogeneity of
studies remains a significant cause of conflicting results
and ethnic variations in genotype-phenotype association
must be examined closely.
Abbreviations
MA: migraine with aura; MO: migraine without aura; MTHFR: methylene
tetrahydrofolate reductase; SNP: single nucleotide polymorphism
Acknowledgements
Study Funding: Medical Research Council (MRC)
Author details
1Department of Psychiatry and Behavioural Neurosciences, McMaster
University, Hamilton, ON, Canada. 2Medical Research Council (MRC) Social
Genetic and Developmental Psychiatry Centre, Institute of Psychiatry,
London, UK. 3Department of Psychological Medicine, School of Medicine,
Cardiff University, Cardiff, UK. 4Division of Neuroscience, University of
Birmingham, Birmingham, UK. 5Barts and The London, Queen Mary’s School
of Medicine and Dentistry, London, UK. 6Clinical Epidemiology and
Biostatistics, McMaster University, Hamilton, ON, Canada.
Authors’ contributions
ZS conceived the migraine study, designed the migraine interviews,
collected data, analyzed data and wrote the 1st draft. With AM. ZS also
performed literature search for meta-analysis. DG and SCW performed all
DNA related lab experiments. NC, LJ, AK and MO are investigators on the
depression case control study, designed the original study, were responsible
for the study conduct and recruitment, supervision of study personnel and
contributed to the manuscript. AM performed literature search for the mea-
analysis and run the analysis for this part of the study, he also contributed
to the manuscript writing. PM and AF are the depression case control study
PIs and the supervisors of the 1st author; they guided the study with
significant input into the design of the migraine study and selection of gene
variant, they also contributed to the writing of the manuscript and provided
Samaan et al. BMC Neurology 2011, 11:66
http://www.biomedcentral.com/1471-2377/11/66
Page 7 of 9
the resources for the migraine study. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 16 December 2010 Accepted: 2 June 2011
Published: 2 June 2011
References
1. ICHD-II: The International Classification of Headache Disorders. 2nd
Edition. Cephalalgia 2004, 24(s1):8-160.
2. Samaan Z, Farmer A, Craddock N, Jones L, Korszun A, Owen M,
Williamson R, McGuffin P: A Case- Control Study of Migraine in Recurrent
Depression. British Journal of Psychiatry 2009, 194:350-354.
3. Merikangas KR: Psychopathology and headache syndromes in the
community. Headache 1994, 34(8):S17-S22.
4. Breslau N, Lipton R, Stewart W, Schultz L, Welch K: Comorbidity of
migraine and depression. Investigating potential etiology and prognosis.
Neurology 2003, 60:1308-1312.
5. Lipton R, Hamelsky S, Kolodner K, Steiner TJ, Stewart W: Migraine, quality
of life, and depression. Neurology 2000, 55:629-635.
6. Ball HA, Samaan Z, Brewster S, Craddock N, Gill M, Korszun A, Maier W,
Middleton L, Mors O, Owen MJ, Perry J, Preisig M, Rice J, Rietschel M,
Jones L, Jones I, Farmer AE, McGuffin P: Depression, migraine with aura
and migraine without aura: their familiality and interrelatedness.
Cephalalgia 2009, 29(8):848-854.
7. Kendler KS, Prescott CA: A Population-Based Twin Study of Lifetime Major
Depression in Men and Women. Arch Gen Psychiatry 1999, 56(1):39-44.
8. Cologno D, De Pascale A, Manzoni GC: Familial Occurrence of Migraine
With Aura in a Population-Based Study. Headache 2003, 43(3):231-234.
9. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG,
Boers GJH, den Heijer M, Kluijtmans LAJ, van den Heuve LP, Rozen R: A
candidate genetic risk factor for vascular disease: a common mutation
in methylenetetrahydrofolate reductase. Nature Genet 1995, 10(1):111-113.
10. Moschiano F, D’Amico D, Usai S, Grazzi L, Di Stefano M, Ciusani E, Erba N,
Bussone G: Homocysteine plasma levels in patients with migraine with
aura. Neurological Sciences 2008, 29(0):173-175.
11. Kara I, Sazci A, Ergul E, Kaya G, Kilic G: Association of the C677T and
A1298C polymorphisms in the 5,10 methylenetetrahydrofolate reductase
gene in patients with migraine risk. Brain Research Molecular Brain
Research 2003, 111(1-2):84-90.
12. Kowa H, Yasui K, Takeshima T, Urakami K, Sakai F, Nakashima K: The
homozygous C677T mutation in the methylenetetrahydrofolate
reductase gene is a genetic risk factor for migraine. American Journal of
Medical Genetics 2000, 96(6):762-764.
13. Lea R, Ovcaric M, Sundholm J, MacMillan J, Griffiths L: The
methylenetetrahydrofolate reductase gene variant C677T influences
susceptibility to migraine with aura. BMC Medicine 2004, 2(1):3.
14. Scher AI, Terwindt GM, Verschuren WMM, Kruit MC, Blom HJ, Kowa H,
Frants RR, van den Maagdenberg AMJM, van Buchem M, Ferrari MD,
Launer LJ: Migraine and MTHFR C677T genotype in a population-based
sample. Annals of Neurology 2006, 59(2):372-375.
15. Oterino A, Valle N, Bravo Y, Munoz P, Sanchez-Velasco P, Ruiz-Alegria C,
Castillo J, Leyva-Cobian F, Vadillo A, Pascual J: MTHFR T677 homozygosis
influences the presence of aura in migraineurs. Cephalalgia 2004,
24(6):491-494.
16. Todt U, Freudenberg J, Goebel I, Netzer C, Heinze A, Heinze-Kuhn K,
Göbel H, Kubisch C: MTHFR C677T polymorphism and migraine with
aura. Annals of Neurology 2006, 60(5):621-622.
17. Kaunisto M, Kallela M, Hamalainen E, Kilpikari R, Havanka H, Harno H,
Nissila M, Sako E, Ilmavirta M, Liukkonen J, Teirmaa H, Tornwall O, Jussila M,
Terwilliger J, Farkkila M, Kaprio J, Palotie A, Wessman M: Testing of variants
of the MTHFR and ESR1 genes in 1798 Finnish individuals fails to
confirm the association with migraine with aura. Cephalalgia 2006,
26(12):1462-1472.
18. Gilbody S, Lewis S, Lightfoot T: Methylenetetrahydrofolate Reductase
(MTHFR) Genetic Polymorphisms and Psychiatric Disorders: A HuGE
Review. Am J Epidemiol 2007, 165(1):1-13.
19. Gaysina D, Cohen S, Craddock N, Farmer A, Hoda F, Korszun A, Owen MJ,
Craig IW, McGuffin P: No association with the 5,10-
methylenetetrahydrofolate reductase gene and major depressive
disorder: Results of the depression case control (DeCC) study and a
meta-analysis. American Journal of Medical Genetics Part B: Neuropsychiatric
Genetics 2008, 147B(6):699-706.
20. Farmer A, Korszun A, Owen MJ, Craddock N, Jones L, Jones I, Gray J,
Williamson RJ, McGuffin P: Medical disorders in people with recurrent
depression. The British Journal of Psychiatry 2008, 192(5):351-355.
21. Nash MW, Huezo-Diaz P, Williamson RJ, Sterne A, Purcell S, Hoda F,
Cherny SS, Abecasis GR, Prince M, Gray JA, Ball D, Asherson P, Mann A,
Goldberg D, McGuffin P, Farmer A, Plomin R, Craig IW, Sham PC: Genome-
wide linkage analysis of a composite index of neuroticism and mood-
related scales in extreme selected sibships. Hum Mol Genet 2004,
13(19):2173-2182.
22. Wing JK, Babor T, Burgha T: SCAN. Schedule for the Clinical Assessment
of Neuropsychiatry. Archives of General Psychiatry 1990, 47:589-593.
23. McGuffin P, Katz R, Aldrich J: Past and present state examination: the
assessment of ‘lifetime ever’ psychopathology. Psychological Medicine
1986, 16(2):461-465.
24. Samaan Z, MacGregor EA, Dowson A, McGuffin P, Farmer A: Diagnosing
migraine in research and clinical settings: development and validation
of the Structured Migraine Interview (SMI). BMC Neurology 2010,
10:10-17.
25. DerSimonian R, Laird N: Meta-analysis in clinical trials. Controlled Clin Trials
1986, 7:177-188.
26. Schurks M, Zee RYL, Buring JE, Kurth T: Interrelationships among the
MTHFR 677C > T polymorphism, migraine, and cardiovascular disease.
Neurology 2008, 71(7):505-513.
27. Schürks M, Zee RYL, Buring JE, Kurth T: MTHFR 677CT & 2192;T and ACE
D/I polymorphisms and migraine attack frequency in women.
Cephalalgia 2009.
28. Joshi G, Pradhan S, Mittal B: Role of the ACE ID and MTHFR C677T
polymorphisms in genetic susceptibility of migraine in a north Indian
population. Journal of the Neurological Sciences 2009, 277(1-2):133-137.
29. Ferro A, Castro MJ, Lemos C, Santos M, Sousa A, Pereira-Monteiro J,
Sequeiros J, Maciel P: The C677T polymorphism in MTHFR is not
associated with migraine in Portugal. Disease Markers 2008, 25(2):107-113.
30. Rubino E, Ferrero M, Rainero I, Binello E, Vaula G, Pinessi L: Association of
the C677T Polymorphism in the MTHFR Gene with Migraine: A Meta-
Analysis. Cephalalgia 2009, 29(8):818-825.
31. Schürks M, Rist PM, Kurth T: MTHFR 677C > T and ACE D/I Polymorphisms
in Migraine: A Systematic Review and Meta-Analysis. Headache: The
Journal of Head and Face Pain 2010, 50(4):588-599.
32. Lewis SJ, Lawlor DA, Davey Smith G, Araya R, Timpson N, Day INM,
Ebrahim S: The thermolabile variant of MTHFR is associated with
depression in the British Women’s Heart and Health Study and a meta-
analysis. Molecular Psychiatry 2006, 11(4):352-360.
33. Kelly CB, McDonnell AP, Johnston TG, Mulholland C, Cooper SJ,
McMaster D, Evans A, Whitehead AS: The MTHFR C677T polymorphism is
associated with depressive episodes in patients from Northern Ireland. J
Psychopharmacol 2004, 18(4):567-571.
34. Arinami T, Yamada N, Yamakawa-Kobayashi K, Hamaguchi H, Toru M:
Methylenetetrahydrofolate reductase variant and schizophrenia/
depression. American Journal of Medical Genetics 1997, 74(5):526-528.
35. Bjelland I, Tell GS, Vollset SE, Refsum H, Ueland PM: Folate, vitamin B12,
homocysteine, and the MTHFR 677C- > T polymorphism in anxiety and
depression: the Hordaland Homocysteine Study. Archives of General
Psychiatry 2003, 60(6):618-626.
36. Seo JH, Kim HJ, Lee IH, Kim OJ, Choi BO: Association between Migraine
with Aura and both Homocysteine and MTHFR C677T Polymorphism. J
Korean Neurol Assoc 2004, 22(3):200-205.
37. Oterino A, Valle N, Pascual J, Bravo Y, Munoz P, Castillo J, Ruiz-Alegria C,
Sanchez-Velasco P, Leyva-Cobian F, Cid C: Thymidylate synthase promoter
tandem repeat and MTHFD1 R653Q polymorphisms modulate the risk
for migraine conferred by the MTHFR T677 allele. Molecular Brain
Research 2005, 139(1):163-168.
38. Bottini F, Celle ME, Calevo MG, Amato S, Minniti G, Montaldi L, Di
Pasquale D, Cerone R, Veneselli E, Molinari AC: Metabolic and genetic risk
factors for migraine in children. Cephalalgia 2006, 26(6):731-737.
39. Pezzini A, Grassi M, Del Zotto E, Giossi A, Monastero R, Dalla Volta G,
Archetti S, Zavarise P, Camarda C, Gasparotti R, Magoni M, Camarda R,
Padovani A: Migraine Mediates the Influence of C677T MTHFR
Samaan et al. BMC Neurology 2011, 11:66
http://www.biomedcentral.com/1471-2377/11/66
Page 8 of 9
Genotypes on Ischemic Stroke Risk With a Stroke-Subtype Effect. Stroke
2007, 38(12):3145-3151.
40. Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD: Homocysteine
and stroke: evidence on a causal link from mendelian randomisation.
The Lancet 2005, 365(9455):224-232.
41. Alpert JE, Mischoulon D, Nierenberg AA, Fava M: Nutrition and depression:
focus on folate. Nutrition 2000, 16(7-8):544-546.
42. Di Rosa G, Attina S, Spano M, Ingegneri G, Sgro DL, Pustorino G,
Bonsignore M, Trapani-Lombardo V, Tortorella G: Efficacy of Folic Acid in
Children With Migraine, Hyperhomocysteinemia and MTHFR
Polymorphisms. Headache: The Journal of Head and Face Pain 2007,
47(9):1342-1344.
43. Agustin O, Maria T, Natalia V, Jesus C, Ana AA, Yolanda B, Carlos RA,
Estrella Q, Julio P: The Relationship Between Homocysteine and Genes of
Folate-Related Enzymes in Migraine Patients. Headache: The Journal of
Head and Face Pain 2009, 50(1):99-168.
44. Joshi G, Pradhan S, Mittal B: Role of the ACE ID and MTHFR C677T
polymorphisms in genetic susceptibility of migraine in a north Indian
population. Journal of the Neurological Sciences 2009, 277(1):133-137.
45. de Tommaso M, Difruscolo O, Sardaro M, Losito L, Serpino C,
Pietrapertosa A, Santeramo MT, Dicuonzo F, Carella A, Lamberti P, Livrea P:
Influence of MTHFR Genotype on Contingent Negative Variation And
MRI Abnormalities in Migraine. Headache: The Journal of Head and Face
Pain 2007, 47(2):253-265.
46. Bottini F, Celle M, Calevo M, Amato S, Minniti G, Montaldi L, Pasquale DD,
Cerone R, Veneselli E, Molinari A: Metabolic and genetic risk factors for
migraine in children. Cephalalgia 2006, 26(6):731-737.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2377/11/66/prepub
doi:10.1186/1471-2377-11-66
Cite this article as: Samaan et al.: Methylenetetrahydrofolate Reductase
Gene Variant (MTHFR C677T) and Migraine: A Case Control Study and
Meta-analysis. BMC Neurology 2011 11:66.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Samaan et al. BMC Neurology 2011, 11:66
http://www.biomedcentral.com/1471-2377/11/66
Page 9 of 9
